Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer.
Nom du journal : Eur J Cancer
Année : 2024
Volume : 209
Page de départ : 114183
